Antithrombotic Therapy After Lower Limb Angioplasty

Periprocedural Anticoagulation

• Unfractionated heparin (UFH) 60 IU/kg IV bolus with a target activated clotting time of 250–350 seconds (without glycoprotein IIb/IIIa inhibitors) is the standard intraprocedural anticoagulant for lower‑limb angioplasty. Class I recommendation – European Society of Cardiology. 1
• Alternative intraprocedural options include a single IV bolus of low‑molecular‑weight heparin (enoxaparin 0.75 mg/kg) when the last subcutaneous dose was >12 hours earlier, or a bivalirudin regimen (0.75 mg/kg bolus followed by 1.75 mg/kg/h infusion). Class IIa – European Society of Cardiology. 1
• Post‑procedure anticoagulation should be discontinued unless a specific thrombotic complication occurs. Class I – European Society of Cardiology. 1

First‑Line Post‑Procedural Regimen (Class I)

• Low‑dose rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily reduces major adverse cardiovascular events (myocardial infarction, stroke, cardiovascular death) and major adverse limb events (acute limb ischemia, major amputation, urgent revascularization) after lower‑limb angioplasty. Class I, Level A – American College of Cardiology (ACC) 2024 guideline. 2
• The same low‑dose rivaroxaban‑aspirin combination is recommended for long‑term therapy in patients with symptomatic peripheral artery disease (PAD) after revascularization, providing ongoing cardiovascular and limb protection. Class I – ACC 2024. 2

Alternative Regimen When Rivaroxaban Is Contraindicated (Class IIa)

• Dual antiplatelet therapy (DAPT) with clopidogrel 75 mg daily plus aspirin 81 mg daily for 1–6 months is reasonable after endovascular revascularization, especially when rivaroxaban cannot be used. Class IIa, Level B – European Society of Cardiology 2024. 3
• After completing the 1–6 month DAPT course, patients should transition to single antiplatelet therapy for long‑term management. Class IIa – ACC 2024. 4

Single Antiplatelet Options

• Clopidogrel 75 mg daily alone may be preferred over aspirin for symptomatic PAD patients when dual therapy or rivaroxaban‑aspirin is not feasible. Class IIb – ACC 2024. 5
• Aspirin 75–325 mg daily alone is an acceptable alternative single‑agent strategy. Class IIb – ACC 2024. 5

Patients Requiring Full‑Intensity Anticoagulation for Other Indications

• In patients already on therapeutic anticoagulation (e.g., atrial fibrillation, mechanical valve) add a single antiplatelet agent (aspirin 81 mg daily) rather than using triple therapy. Class I – ACC 2024. 2
• Avoid triple therapy (dual antiplatelet plus full‑intensity anticoagulation) because of excessive bleeding risk. Class III, Harm – Circulation 2011. 6

Contraindicated Therapy

• Full‑intensity oral anticoagulation alone (warfarin or therapeutic‑dose DOACs) should not be used in PAD patients without another indication, as it fails to reduce MACE or MALE and increases bleeding. Class III, Harm – ACC 2024 and Circulation 2011. 7

Special Situations

• Surgical bypass with prosthetic graft: DAPT (clopidogrel + aspirin) may be reasonable for at least 1 month (Class IIb). Class IIb – ACC 2024. 2

Safety Considerations

• The low‑dose rivaroxaban regimen (2.5 mg BID) is essential; it differs from the standard 20 mg dose used for atrial fibrillation. Class I – ACC 2024. 2
• Major bleeding risk is higher with rivaroxaban‑aspirin compared with aspirin alone, but the reduction in cardiovascular and limb events outweighs this risk in most patients. Class I – ACC 2024 and European Society of Cardiology 2024. 3

Low‑Dose Rivaroxaban + Aspirin After Iliac Artery Revascularization

Initiation Timing

• Initiate low‑dose rivaroxaban 2.5 mg twice daily together with aspirin once hemostasis at the vascular access site is confirmed after iliac artery angioplasty and stenting. This recommendation follows the European Society of Cardiology (ESC) 2024 guidance and is supported by a Class I recommendation. 8

Long‑Term Antithrombotic Strategy

• The preferred chronic regimen for patients without a high bleeding risk is rivaroxaban 2.5 mg twice daily plus aspirin 75–100 mg once daily. The ESC 2024 guidelines assign this combination a Class IIa, Level A recommendation for peripheral artery disease (PAD) after lower‑limb revascularization. 8
• Therapy should be continued indefinitely to maintain cardiovascular and limb protection in symptomatic PAD after revascularization; ongoing treatment is associated with sustained mortality and limb‑event reductions. 8

Alternative Regimens When Rivaroxaban Is Contraindicated

• Dual antiplatelet therapy (clopidogrel 75 mg daily + aspirin 81–100 mg daily) for 1–3 months is an acceptable alternative when rivaroxaban cannot be used, after which patients should transition to single‑antiplatelet therapy (either aspirin or clopidogrel). 8

Bleeding‑Risk Assessment and Tailored Therapy

• High bleeding risk is defined by any of the following: dialysis dependence or eGFR < 15 mL/min/1.73 m², acute coronary syndrome within the prior 30 days, prior intracranial hemorrhage, prior stroke or TIA, or active/significant bleeding. In such patients, single‑antiplatelet therapy alone is preferred over the rivaroxaban‑aspirin combination. 8

Dosing and Renal Considerations

• The correct dose for PAD is 2.5 mg twice daily; it differs from the 20 mg daily dose used for atrial fibrillation and the 10 mg daily dose used for venous‑thromboembolism prophylaxis. The medication may be taken with or without food. 8
• No renal dose adjustment is required for the 2.5 mg twice‑daily regimen, but the drug should be avoided when creatinine clearance is < 15 mL/min, in accordance with FDA labeling. 8

Antiplatelet Therapy Management After Hematoma in Patients with Lower‑Extremity Stents

Immediate Management

• Discontinue clopidogrel and maintain aspirin 75–100 mg daily as monotherapy for long‑term cardiovascular and limb protection after a large hematoma develops one year post‑stent, because the mandatory 1–3 month dual‑antiplatelet period has elapsed and bleeding risk now outweighs any marginal thrombotic benefit【9】.

Recommended Long‑Term Antiplatelet Regimen

• The 2024 European Society of Cardiology (ESC) guidelines state that, after the initial 1–3 month dual‑antiplatelet phase, patients with symptomatic peripheral artery disease should receive single antiplatelet therapy (aspirin or clopidogrel) as the standard long‑term regimen【9】.
• Continuing aspirin indefinitely (unless a new contraindication appears) reduces major adverse cardiovascular events and limb events in all patients with peripheral artery disease【9】.

Alternative Antithrombotic Consideration (When No Active Bleeding)

• Once the hematoma has fully resolved and the patient possesses high‑risk features (e.g., diabetes, heart failure, prior amputation, chronic limb‑threatening ischemia, or multivessel disease), the ESC recommends transitioning to low‑dose rivaroxaban 2.5 mg twice daily combined with aspirin as the preferred long‑term regimen for additional cardiovascular and limb‑event reduction【9】.
• In the presence of an active hematoma, initiating a rivaroxaban‑aspirin combination is contraindicated because it would further increase bleeding risk【9】.

Special Population Considerations

• A history of ocular disease does not preclude aspirin monotherapy, but dual antiplatelet therapy or rivaroxaban‑aspirin combinations should be avoided in patients with active ocular surface disease or recent ocular hemorrhage due to heightened bleeding risk【9】.

Monitoring After De‑escalation

• After stopping clopidogrel, clinicians should assess for hematoma expansion or new bleeding within 48–72 hours.
• Limb‑ischemia symptoms (e.g., rest pain, new claudication, tissue loss) should be monitored during the first 2–4 weeks; the risk of acute stent thrombosis at one year post‑procedure is extremely low (<0.5 % per year)【9】.

Common Pitfalls to Avoid

• Continuing dual antiplatelet therapy beyond 3 months in patients who develop bleeding complications is guideline‑discordant and increases morbidity without providing mortality benefit【9】.
• Substituting clopidogrel for aspirin in this bleeding scenario is not recommended; aspirin is preferred for its cost‑effectiveness and familiarity【9】.